FACTS ABOUT NEW ADVANCEMENTS IN BRD4 INHIBITION THERAPY ABBV-744 REVEALED

In Segment A, participants will acquire unique doses and schedules of oral ABBV-744 tablet to determine Secure dosing program. Added individuals are going to be enrolled for the recognized monotherapy dosign program. In Section B, participants will get oral ruxolitinib and ABBV-744 will likely be offered as "add-on" therapy. In Phase C, members wil